Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm's Phase 2b interim trial of 18F-RAD101 met its primary endpoint, showing 93% concordance between PET and MRI across evaluable brain-metastasis lesions; 14 patients with follow-up and/or biopsy data also showed preliminary sensitivity of 86%. The company will meet with the FDA on October 1 to align on a global pivotal Phase 3 protocol, supported by Fast Track designation and Siemens Healthineers manufacturing/distribution collaboration. RAD101 targets an estimated approximately $600 million brain-metastases imaging market with no currently approved PET products.

Analysis

RADX’s valuation can re-rate on protocol de-risking rather than on the interim dataset itself: concordance with an imperfect comparator does not establish the clinically decisive endpoint of distinguishing recurrence from radiation necrosis. The investable question is whether FDA accepts a practical reference-standard design and an endpoint that avoids broad biopsy requirements; a burdensome design would extend enrollment, raise cash burn, and increase dilution risk. The October FDA interaction is therefore the near-term binary catalyst, with the November presentation a secondary validation event only if it supplies lesion-level specificity, confidence intervals, and outcomes versus pathology/follow-up.

The addressable-market framing likely overstates near-term revenue because imaging adoption depends on reimbursement, scan workflow, and whether RAD101 changes treatment decisions sufficiently to displace serial MRI rather than merely supplement it. F-18 distribution creates a plausible commercial advantage over short-half-life tracers, but Siemens Healthineers’ manufacturing relationship is strategically useful to RADX while financially immaterial to SHL. Competitive risk is less another approved brain-metastasis PET agent than continued improvement in advanced MRI, amino-acid PET use at specialized centers, and payer reluctance absent prospective management-impact data.

Consensus may treat Fast Track and late-breaking selection as efficacy validation; neither resolves diagnostic specificity or regulatory endpoint risk. For the next 1-3 months, RADX is a high-volatility catalyst trade, not a fundamental revenue story. Over 6-18 months, financing terms, Phase 3 size and duration, and reimbursement evidence will dominate clinical enthusiasm; failure to disclose robust specificity or a favorable FDA path should compress the option value embedded in the shares.

Key Decisions for Investors

• Maintain RADX as a small, event-driven long only into the October 1 FDA protocol update; size at venture-biotech risk levels (<50 bps NAV) and take partial profits on a sharp pre-event rally. Add only if management discloses a feasible pivotal design, clear primary endpoint, and enrollment timeline; adverse protocol complexity is thesis-invalidating.
• Do not underwrite the stated market opportunity until the SNO presentation provides lesion-level sensitivity and specificity with confidence intervals, reference-standard methodology, and evidence that scans alter management. If specificity is weak or the evaluable reference-standard cohort remains small, avoid chasing any conference-driven move.
• Use a defined-risk structure where liquid options permit—long dated calls or call spreads rather than common-stock leverage—to retain upside through the FDA/SNO catalysts while capping expected Phase 3 financing dilution exposure over the next 6-12 months.
• No actionable SHL or FTRK trade: the manufacturing arrangement is unlikely to move Siemens earnings, and the supplied data provide no fundamental linkage to FTRK. Monitor SHL only for evidence that its PET distribution network becomes a broader radiopharma toll-road franchise.